Clinical Trial Update: Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating nivolumab plus ipilimumab or standard-of-care chemotherapy versus standard-of-care chemotherapy alone in untreated, inoperable or met…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• Standard of care chemotherapy
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Urothelial Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-09-18